AGC Pharma Chemicals Validates New Barcelona CDMO Facility Through Scientist.com’s VERIF.i® Supplier Assessment Program
AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) specializing in small molecule active pharmaceutical ingredients (APIs) and highly potent active pharmaceutical ingredients (HPAPIs), has successfully completed an onsite assessment of its newly expanded Barcelona manufacturing facility through Scientist.com’s VERIF.i® supplier pre-assessment program. The milestone highlights the company’s continued commitment to quality, operational excellence, regulatory compliance, and transparency as it expands its global pharmaceutical manufacturing capabilities.
The assessment was conducted in partnership with Scientist.com, the life sciences industry’s leading AI-enabled research and development orchestration platform and digital marketplace. By successfully completing the independent onsite evaluation, AGC Pharma Chemicals further demonstrates that its new Barcelona facility meets internationally recognized operational and management standards while reinforcing customer confidence in its manufacturing and development capabilities.
The completion of the VERIF.i assessment comes at an important time for AGC Pharma Chemicals as demand continues to grow for reliable contract development and manufacturing partners capable of supporting increasingly complex pharmaceutical programs. The company’s expanded Barcelona site significantly enhances its ability to provide integrated development and manufacturing services for both traditional small molecules and highly potent compounds across multiple stages of drug development and commercialization.
Expanding Global Manufacturing Capacity
The newly expanded Barcelona facility represents an important investment in AGC Pharma Chemicals’ long-term growth strategy and strengthens its position within the global CDMO market.
As pharmaceutical companies increasingly outsource development and manufacturing activities to specialized contract organizations, demand has risen for facilities capable of delivering flexible, scalable, and high-quality manufacturing services that meet stringent regulatory expectations.
The Barcelona expansion is designed to address these evolving industry requirements by providing comprehensive end-to-end manufacturing capabilities that support projects from early-stage process development through commercial-scale production.
The facility enables production ranging from gram-scale quantities required during early research and clinical development to ton-scale manufacturing needed for commercial pharmaceutical products.
This broad manufacturing capability allows customers to work with a single development and manufacturing partner throughout the entire lifecycle of a pharmaceutical program, simplifying technology transfer, reducing operational complexity, and improving project continuity.
Supporting Complex APIs and Highly Potent Compounds
One of the defining characteristics of the expanded Barcelona site is its specialized capability for manufacturing complex small molecule active pharmaceutical ingredients and highly potent APIs.
Small molecule drugs continue to represent a substantial portion of approved pharmaceutical products worldwide. However, modern small molecule therapies are becoming increasingly sophisticated, requiring advanced synthetic chemistry, specialized containment systems, and highly controlled manufacturing environments.
Highly potent active pharmaceutical ingredients present even greater manufacturing challenges due to their pharmacological activity and the stringent occupational safety measures required during production.
Manufacturing HPAPIs demands advanced containment technologies, rigorous engineering controls, specialized operator training, and strict adherence to safety protocols that protect employees while ensuring product quality.
The expanded Barcelona facility has been designed to address these technical challenges by incorporating advanced production technologies alongside flexible manufacturing infrastructure capable of accommodating a wide range of complex chemical processes.
This investment enables AGC Pharma Chemicals to support pharmaceutical innovators developing increasingly sophisticated therapies across numerous therapeutic areas.
Facility Designed for Flexibility and Sustainability
In addition to expanding manufacturing capacity, AGC Pharma Chemicals has emphasized flexibility, operational safety, and environmental sustainability in the design of the Barcelona facility.
Modern pharmaceutical manufacturing requires facilities capable of adapting rapidly to changing customer needs, varying production volumes, and evolving regulatory requirements.
The Barcelona site has therefore been engineered to provide flexible manufacturing environments that can accommodate diverse development and commercial manufacturing programs while maintaining consistent quality standards.
Operational safety also remains a central priority, particularly when handling highly potent compounds requiring specialized containment and worker protection measures.
Alongside operational performance, the facility incorporates energy-efficient technologies and sustainability initiatives intended to reduce environmental impact while supporting responsible pharmaceutical manufacturing practices.
These design considerations reflect broader industry efforts to balance production efficiency with environmental stewardship and long-term sustainability goals.
Independent Assessment Through VERIF.i®
The successful completion of the VERIF.i supplier pre-assessment represents an additional layer of independent validation for the Barcelona facility.
VERIF.i was developed by Scientist.com to provide regulated research service providers—including organizations involved in chemistry, manufacturing, and controls (CMC)—with an objective mechanism for demonstrating their operational capabilities to pharmaceutical and biotechnology customers.
Unlike traditional customer audits that require each sponsor company to conduct separate onsite assessments, VERIF.i establishes a standardized evaluation process that can be utilized by multiple organizations during supplier qualification.
The assessments are performed by experienced independent third-party auditors, helping ensure objectivity while providing consistent evaluations based on recognized industry standards.
The resulting assessments allow suppliers to proactively demonstrate their operational readiness, management systems, quality programs, and manufacturing capabilities before individual customer audits are initiated.
This proactive approach helps streamline supplier qualification while improving transparency throughout the procurement process.
Reinforcing Commitment to Quality
Jun Kurihara, Chief Executive Officer of AGC Pharma Chemicals, emphasized that operational excellence remains central to the company’s business strategy.
According to Kurihara, AGC places the highest priority on maintaining robust operational processes and supporting the expertise of its manufacturing teams.
He explained that participation in the VERIF.i assessment program enables the company to independently demonstrate compliance with internationally recognized management standards while showcasing the strength of its production oversight systems.
Successfully completing the assessment reinforces AGC Pharma Chemicals’ commitment to transparency and continuous quality improvement, providing customers with additional confidence in the organization’s manufacturing operations.
Kurihara noted that maintaining high standards across manufacturing, quality management, and operational oversight remains essential as pharmaceutical companies increasingly seek reliable long-term CDMO partners capable of supporting complex development programs.
Addressing Procurement Challenges
Supplier qualification represents one of the most resource-intensive aspects of pharmaceutical outsourcing.
Before selecting manufacturing partners, pharmaceutical and biotechnology companies typically conduct extensive due diligence processes to evaluate regulatory compliance, quality systems, manufacturing capabilities, technical expertise, and operational performance.
These evaluations often include detailed onsite audits requiring significant investments of time and personnel from both customers and suppliers.
Scientist.com’s VERIF.i program seeks to reduce this burden by creating standardized independent assessments that provide valuable information during early supplier evaluation.
Because assessments are conducted by experienced third-party auditors following established industry criteria, pharmaceutical companies can review objective evaluation findings before determining whether additional site-specific audits are necessary.
This process can substantially accelerate supplier qualification while reducing duplication of effort across multiple customer organizations.
Scientist.com Highlights Benefits of Standardized Assessments
Matt McLoughlin, Senior Vice President of Compliance and Categories at Scientist.com, highlighted the importance of independent supplier evaluations within regulated pharmaceutical services.
According to McLoughlin, sourcing regulated services carries significant reputational and operational risk for pharmaceutical companies, making thorough supplier qualification an essential component of procurement.
Traditional onsite assessments, however, often require considerable financial and personnel resources from both buyers and suppliers.
He explained that VERIF.i addresses these challenges by establishing a standardized pre-assessment process that improves efficiency while maintaining rigorous evaluation standards.
The program enables high-performing suppliers such as AGC Pharma Chemicals to distinguish themselves by providing customers with actionable, independently verified insights regarding facility operations, quality systems, and organizational capabilities.
This approach benefits both pharmaceutical sponsors and service providers by simplifying due diligence while maintaining confidence in supplier selection decisions.
Supporting Pharmaceutical Innovation
The pharmaceutical industry increasingly depends on specialized contract development and manufacturing organizations capable of providing advanced technical expertise across increasingly complex therapeutic programs.
Growing demand for targeted therapies, oncology treatments, highly potent compounds, and specialized manufacturing processes has increased the importance of selecting experienced CDMO partners with proven operational capabilities.
Facilities such as AGC Pharma Chemicals’ expanded Barcelona site provide pharmaceutical companies with access to specialized manufacturing expertise without requiring substantial internal infrastructure investments.
By combining flexible production capacity with rigorous quality systems and independently verified operational standards, CDMOs can help accelerate drug development while supporting reliable commercial manufacturing.
Programs such as VERIF.i further strengthen this ecosystem by enhancing transparency, reducing qualification timelines, and facilitating more efficient collaboration between pharmaceutical innovators and manufacturing partners.
Building on the COMPLi® Platform
VERIF.i represents the latest expansion of Scientist.com’s broader compliance ecosystem, building upon the company’s award-winning COMPLi® platform.
COMPLi was developed to simplify regulatory compliance and supplier qualification across the life sciences industry by providing standardized documentation, verification processes, and digital compliance management tools.
VERIF.i extends these capabilities through independent onsite facility assessments that complement existing documentation and supplier information available through the platform.
Together, these solutions help pharmaceutical companies make more informed procurement decisions while reducing administrative burdens associated with supplier qualification.
As outsourcing continues expanding across pharmaceutical research, development, and manufacturing, digital compliance platforms are becoming increasingly valuable tools for improving operational efficiency throughout the industry.
Strengthening Customer Confidence
The successful completion of the VERIF.i onsite assessment reinforces AGC Pharma Chemicals’ commitment to maintaining world-class manufacturing operations while providing pharmaceutical customers with greater transparency regarding its capabilities.
The expanded Barcelona facility enhances the company’s ability to support complex small molecule and highly potent API development from early-stage research through commercial production, while the independent assessment offers additional assurance regarding operational quality and regulatory readiness.
As pharmaceutical companies continue seeking trusted manufacturing partners capable of delivering high-quality, flexible, and compliant development services, investments in advanced facilities combined with independent verification programs are expected to play an increasingly important role in supplier selection.
Through its continued investment in manufacturing infrastructure, operational excellence, and transparent quality assessment, AGC Pharma Chemicals is positioning itself to meet the evolving needs of global pharmaceutical innovators while supporting the development and commercialization of next-generation medicines for patients worldwide.
About AGC Pharma Chemicals
AGC Pharma Chemicals is a global CDMO specializing in Active Pharmaceutical Ingredients (APIs) and intermediates with facilities in Spain (Barcelona) and Japan. The company is dedicated to providing reliable execution, high-quality standards, and scalable support for small molecule API programs, guiding customers from initial development through to commercialization. Learn more at https://www.agcpharmachemicals.com/.
About Scientist.com
Scientist.com is the leading AI-enabled R&D orchestration platform and online marketplace for the life science industry. The platform simplifies drug discovery and clinical development by:
- Streamlining procurement of complex research services and materials
- Accelerating innovation through faster vendor discovery, competitive bidding and standardized workflows
- Ensuring regulatory and policy compliance via integrated pre-project reviews and oversight
- Connecting scientists with a global network of pre-qualified suppliers that provide highly specialized scientific capabilities, technologies and data assets
Scientist.com powers secure, private marketplaces for many of the world’s largest pharmaceutical companies and hundreds of biotech firms, helping them digitize and harmonize outsourced R&D across discovery, preclinical, translational and clinical research. The company is headquartered in Solana Beach, California, with team members supporting customers and suppliers worldwide.